Navigation Links
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Date:10/6/2008

entage of patients who were free of ocular pain/discomfort, reflected by a VAS score of 0, was superior and statistically significant for the Durezol groups versus the placebo groups in both the QID and BID studies as early as Day 3/4 and throughout the study period.

Six percent of the Durezol QID patients and 3.7% of the Durezol BID patients experienced a criterion increase in intraocular pressure, defined as a pressure of greater than or equal to 21 mmHg and a change from baseline greater than or equal to 10 mmHg at the same visit, compared with 0% in both of the placebo groups.

"Durezol has shown efficacy across multiple endpoints, including pain reduction. I believe it provides a potent new treatment option with a favorable safety profile," commented Dr. Silverstein. "It is a welcome improvement to the armamentarium of ocular pharmaceuticals, particularly since ocular inflammation is common to the majority of conditions that ophthalmologists treat."

About Postoperative Inflammation

More than five million ophthalmic surgeries are performed each year in the United States. Postoperative inflammation and pain are common occurrences following these procedures and if left untreated, can interfere with a patient's visual rehabilitation or lead to further complications. Corticosteroids and non-steroidal anti-inflammatory drugs are commonly used by healthcare professionals following ophthalmic surgery.

About Durezol

Durezol (difluprednate ophthalmic emulsion) 0.05% is a topical ophthalmic corticosteroid for the treatment of inflammation and pain associated with ocular surgery. Difluprednate, the active ingredient in Durezol, is a difluorinated derivative of prednisolone and has potent anti-inflammatory activity. Prior to U.S. approval, the efficacy and safety of difluprednate in ocular inflammatory diseases had been demonstrated in an extensive preclinical and clinical program in Japan. In two U.S. Phase 3 trials evaluating Durez
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/22/2014)... Nov. 22, 2014 (HealthDay News) -- The wide variety ... pose a threat for people with food allergies, an ... are so many types of food allergies that it ... the holidays," Dr. Guha Krishnaswamy, director of allergy and ... in a hospital news release. "If you know ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new ... addition, the company has also offered an attracting discount ... online supplier of wedding dresses, UWDress.com is good at ... wedding guest gowns are provided over 20 colors, which ... selection is famous for high quality. Therefore, its sales ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Developers and plugin ... new plugin entitled FCPX 3D Model bringing the impossible to ... Model allows users to add obj files to FCPX enabling ... Studios. “Blurring the line between professional and armature, FCPX 3D ... Pixel Film Studios allows Final Cut Pro X users to ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/21/2014)... CT (PRWEB) November 21, 2014 CRN ... a veteran radio industry sales professional to its award-winning ... brings 30 years of leadership and sales experience to ... and assume the title of Director of Strategy and ... Development, Robert O’Mara. , Heinemann will handle a wide ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2
... WASHINGTON, Oct. 1 Today the Senate ... secured by,Senator John Kerry (D-Mass.) to extend the ... to increase the transition and,commercialization of products developed ... the thousands of firms that participate in the,program ...
... Board Chair, Named Executive ... Chairman, ... ), a biopharmaceutical company focused on the discovery,and development of drugs for ... that Corey Goodman,Ph.D., will step down today as President and Chief Executive ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... from Positive VENT Trial Presented at ERS 17th ... 1 Emphasys Medical Inc.,today announced the submission ... Food and Drug Administration (FDA) requesting regulatory,approval to ... in,the United States. The Zephyr EBV is a ...
... period of time after leaving the foster care system ... those with stable housing situations, according to a report ... Adolescent Medicine, one of the JAMA/Archives journals. Youth who ... leaving the foster care system appear to have more ...
... Behavioral,Health System, a UHS facility, has announced the ... teens in crisis. The new treatment,center is associated ... http://www.highlandsbhs.com ) in Littleton, Colo. Highlands Behavioral ... of Excellence represents an expansion of the Adolescent,Unit ...
Cached Medicine News:Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: